Human VEGF-D (Highly Pure Recombinant)

<strong>Human VEGF-D (Highly Pure)</strong>_x000D_ <strong>Catalog number:</strong> B2010375_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Volume/Weight:</strong> 10 ug_x000D_ <strong>pH:</strong> 7.4 upon reconstitution_x000D_ <strong>Supplied as:</strong> Lyophilized Powder_x000D_ <strong>Appearance:</strong> Powder_x000D_ <strong>Applications:</strong> highly pure Human VEGF-D (Highly Pure) expressed in HEK 293. This protein acts as a regulator of both angiogenesis and lymphangiogenesis._x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> rHuVEGF-D; Vascular endothelial growth factor D; FIGF_x000D_ <strong>Grade:</strong> Biotechnology grade. All components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Stacker SA, Achen MG. Emerging Roles for VEGF-D in Human Disease._x000D_ Biomolecules. 2018 Jan 4;8(1):1._x000D_ _x000D_ 2: Jha SK, Rauniyar K, Chronowska E, Mattonet K, Maina EW, Koistinen H, Stenman_x000D_ UH, Alitalo K, Jeltsch M. KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D._x000D_ Elife. 2019 May 17;8:e44478._x000D_ _x000D_ 3: Zajkowska M, Lubowicka E, Fiedorowicz W, Szmitkowski M, Jamiołkowski J,_x000D_ Ławicki S. Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor_x000D_ - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the_x000D_ Diagnostics of Breast Cancer. Pathol Oncol Res. 2019 Oct;25(4):1477-1486._x000D_ _x000D_ 4: Kong Y, Han J, Wu X, Zeng H, Liu J, Zhang H. VEGF-D: a novel biomarker for_x000D_ detection of COVID-19 progression. Crit Care. 2020 Jun 23;24(1):373._x000D_ _x000D_ 5: Desforges M, Rogue A, Pearson N, Rossi C, Olearo E, Forster R, Lees M, Sebire_x000D_ NJ, Greenwood SL, Sibley CP, David AL, Brownbill P. In Vitro Human Placental_x000D_ Studies to Support Adenovirus-Mediated VEGF-D^ΔNΔC Maternal Gene_x000D_ Therapy for the Treatment of Severe Early-Onset Fetal Growth Restriction. Hum_x000D_ Gene Ther Clin Dev. 2018 Mar;29(1):10-23._x000D_ _x000D_ 6: Kinashi H, Ito Y, Sun T, Katsuno T, Takei Y. Roles of the TGF-β⁻VEGF-C_x000D_ Pathway in Fibrosis-Related Lymphangiogenesis. Int J Mol Sci. 2018 Aug_x000D_ 23;19(9):2487._x000D_ _x000D_ 7: Oplawski M, Dziobek K, Zmarzły N, Grabarek B, Halski T, Januszyk P, Kuś-_x000D_ Kierach A, Adwent I, Dąbruś D, Kiełbasiński K, Boroń D. Expression Profile of_x000D_ VEGF-C, VEGF-D, and VEGFR-3 in Different Grades of Endometrial Cancer. Curr_x000D_ Pharm Biotechnol. 2019;20(12):1004-1010._x000D_ _x000D_ 8: Sato T, Paquet-Fifield S, Harris NC, Roufail S, Turner DJ, Yuan Y, Zhang YF,_x000D_ Fox SB, Hibbs ML, Wilkinson-Berka JL, Williams RA, Stacker SA, Sly PD, Achen MG._x000D_ VEGF-D promotes pulmonary oedema in hyperoxic acute lung injury. J Pathol. 2016_x000D_ Jun;239(2):152-61._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/32319336/">9: Wada H, Suzuki M, Matsuda M, Ajiro Y, Shinozaki T, Sakagami S, Yonezawa K,_x000D_ Shimizu M, Funada J, Takenaka T, Morita Y, Nakamura T, Fujimoto K, Matsubara H,_x000D_ Kato T, Unoki T, Takagi D, Wada K, Wada M, Iguchi M, Masunaga N, Ishii M,_x000D_ Yamakage H, Kusakabe T, Yasoda A, Shimatsu A, Kotani K, Satoh-Asahara N, Abe M,_x000D_ Akao M, Hasegawa K; ANOX Study Investigators. Distinct Characteristics of VEGF-D_x000D_ and VEGF-C to Predict Mortality in Patients With Suspected or Known Coronary_x000D_ Artery Disease. J Am Heart Assoc. 2020 May 5;9(9):e015761. </a>_x000D_ _x000D_ <strong>Products Related to Human VEGF-D (Highly Pure) </strong> <a href="https://moleculardepot.com/product-category/Proteins/">: Proteins</a>